Q4 2025 · 19 funds · 1000 position changes
A 13F filing is a quarterly report required by the SEC from institutional investment managers with over $100M in assets. It discloses their equity holdings as of the end of each quarter. We track 20 specialist biotech hedge funds and compare their filings quarter-over-quarter to identify new positions, exits, increases, and decreases.
New means the fund initiated a position it didn't hold last quarter. Increased means they added shares to an existing position. Decreased means they trimmed shares. Exited means they sold their entire position. New positions and exits are the strongest signals — they represent active portfolio decisions, not incremental adjustments.
13F filings are due within 45 days of each quarter end (mid-February, mid-May, mid-August, mid-November). We parse new filings from EDGAR as they're published. The data shown reflects the most recent quarter's filings.
The SEC gives institutional managers 45 days after quarter-end to file their 13F. This means the data reflects positions as of the prior quarter-end, not today. Despite the lag, 13F data is valuable because it reveals the conviction-level decisions of biotech's most informed investors — the kind of positions that take months to build.
More free tools
Fund Convergence
Stocks held by 3+ specialist funds
Catalyst Calendar
PDUFA dates & clinical readouts
Insider Trading
Form 4 buys filtered for noise
Cash Runway
Burn rate & dilution risk
Short Squeeze
High DTC + fund buying + catalysts
Signal Rankings
Composite score across all signals
Want AI context on every signal? Start free trial →
Want to know why they made these moves?
BiotechEdge adds AI-powered context to every position change — plus insider signals, catalyst overlays, and watchlist alerts. 14-day free trial, no credit card.